Academic Journals Database
Disseminating quality controlled scientific knowledge

A new extended release formulation (OROS®) of hydromorphone in the management of pain

ADD TO MY LIST
 
Author(s): Sharon M Weinstein

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2009;
Issue: default;
Start page: 75;
Date: 2008;
Original page

ABSTRACT
Sharon M WeinsteinUniversity of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USAAbstract: Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects typical of opioid analgesics. There is a wide interindividual variability of responsiveness to exogenous opioids both in terms of analgesic efficacy and side effects. Optimizing pain management for the individual patient may require sequential trials of opioid medications until the regimen with the most favorable therapeutic ratio of efficacy to side effects is determined.Keywords: analgesics, opioid, hydromorphone, OROSĀ®, extended-release
Affiliate Program      Why do you need a reservation system?